BioStem Technologies, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BSEM research report →
Companywww.biostemtechnologies.com
BioStem Technologies, Inc. , a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
- CEO
- Jason V. Matuszewski
- IPO
- 2015
- Employees
- 2
- HQ
- Pompano Beach, FL, US
Price Chart
Valuation
- Market Cap
- $67.22M
- P/E
- -3.39
- P/S
- -3.55
- P/B
- 2.11
- EV/EBITDA
- -4.02
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 128.16%
- Op Margin
- 78.38%
- Net Margin
- 105.15%
- ROE
- -47.03%
- ROIC
- -42.17%
Growth & Income
- Revenue
- $47.48M · -84.27%
- Net Income
- $-6,580,912 · -120.64%
- EPS
- $-0.39 · -120.00%
- Op Income
- $-689,147
- FCF YoY
- -72.60%
Performance & Tape
- 52W High
- $14.52
- 52W Low
- $3.09
- 50D MA
- $4.77
- 200D MA
- $5.26
- Beta
- 0.20
- Avg Volume
- 61.40K
Get TickerSpark's AI analysis on BSEM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BSEM Coverage
We haven't published any research on BSEM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BSEM Report →